10/11/2022 | CV | Market Commentary: Northern Oil and Gas plays to solid demand; Bilibili active; Alnylam hits new low
|
9/26/2022 | CV | Market Commentary: Convertibles secondary contraction continues; Southwest Airlines lower; Block active
|
9/20/2022 | CV | Market Commentary: Ford convertible notes fall outright, contract dollar-neutral; Alnylam weaker outright
|
9/16/2022 | CV | Market Commentary: Wayfair ‘taken to the woods’; NextEra weakens; Alnylam improves; Array under pressure
|
9/15/2022 | CV | Market Commentary: NextEra equity units contract on debut; Sarepta convertibles add outright; Alnylam gains
|
9/14/2022 | CV | Market Commentary: NextEra on tap; Sarepta convertibles in focus, expand on debut; Alnylam, iQIYI active
|
9/13/2022 | CV | Market Commentary: Sarepta convertibles eyed; Alnylam flat outright, expands on swap; Wayfair falls
|
9/13/2022 | CV | Market Commentary: Morning Commentary: Alnylam convertibles flat outright, expand on swap; Sarepta eyed
|
9/13/2022 | CV | New Issue: Alnylam prices $900 million five-year convertible notes to yield 1%, up 35%
|
9/12/2022 | CV | Market Commentary: Sarepta on tap; Alnylam offering oversubscribed; Wayfair gains continue; Nio, Li Auto up
|
9/12/2022 | CV | Market Commentary: Morning Commentary: Alnylam Pharmaceuticals convertible notes offering in focus early
|
9/12/2022 | CV | Alnylam talks $900 million five-year convertible notes to yield 1.25%-1.75%, up 30%-35%
|
5/11/2021 | SP | New Issue: Credit Suisse prices $10 million buffered contingent coupon autocallable yield notes on Alnylam Pharmaceuticals
|
2/1/2021 | SP | New Issue: Credit Suisse prices $10 million buffered contingent coupon autocallable yield notes on Alnylam Pharmaceuticals
|
12/23/2020 | SP | New Issue: JPMorgan prices $10 million contingent interest autocallables on Alnylam
|
11/19/2020 | SP | New Issue: Credit Suisse sells $10 million autocallable fixed-income securities on Alnylam
|
9/2/2020 | SP | New Issue: Goldman prices $1.2 million leveraged basket-linked notes on 20 stocks
|
4/24/2020 | SP | New Issue: Goldman prices $1.73 million leveraged basket-linked notes on 19 stocks
|
4/13/2020 | PV | Alnylam Pharmaceuticals gets $750 million term loan with GSO Capital
|
1/3/2018 | BK | Alnylam repays $120 million term loan via Bank of America
|
5/2/2016 | BK | Alnylam gets $120 million BofA term loan, $30 million Wells term loan
|
5/26/2015 | SP | New Issue: Barclays prices $1 million 18.5% callable yield notes linked to Alnylam
|
5/8/2015 | SP | New Issue: JPMorgan prices $1 million 19.6% autocallable reverse exchangeables on Alnylam
|
4/20/2015 | SP | New Issue: JPMorgan prices $2 million 18.85% autocallable reverse exchangeables on Alnylam
|
1/27/2015 | PP | Alnylam secures $79.79 million through private placement of its shares
|
12/1/2014 | SP | New Issue: Credit Suisse prices $1 million 16.1% autocallable reverse convertibles on Alnylam
|
12/21/2012 | HYPF | Alnylam files automatic shelf registration for debt, stock, preferreds
|
7/21/2011 | HYPF | Alnylam files $150 million shelf covering debt, stock, preferreds
|
5/8/2008 | PP | New Issue: Alnylam pockets $5.41 million in private placement of shares
|
11/9/2006 | BT | Market Commentary: Thermage, ActivBiotics IPOs on tap at lower ranges; Millennium, Elan market bonds; Vasogen off
|
11/9/2006 | BT | Alnylam Pharmaceuticals files $150 million stock shelf
|
11/3/2006 | BT | Alnylam cut to peer perform by Bear Stearns
|
11/2/2006 | BT | Alnylam ends quarter with $120.3 million of cash, expects to end year with over $115 million
|
10/31/2006 | BT | Market Commentary: Alnylam, CytRx gain with Sirna; Antigenics gains; Viragen sinks; ZymoGenetics off ahead of results
|
10/30/2006 | BT | Market Commentary: Sirna soars after hours on Merck $1.1 billion buyout; Emisphere plunges 24%; Point better by 19%
|
9/26/2006 | BT | Alnylam grants Quark InterfeRx license to develop RNAi therapeutics
|
9/20/2006 | BT | Biogen Idec, Alnylam to develop RNAi therapeutics for treatment of PML
|
9/8/2006 | BT | Market Commentary: Discovery Labs spikes on buyout buzz; Cell Genesys loses 5% on bought deal; Oscient buffeted
|
9/7/2006 | BT | Alnylam to announce new development program, file IND for pandemic flu before yearend
|
9/6/2006 | BT | Alnylam awarded $590,000 grant to develop pandemic flu drugs
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/21/2006 | BT | Alnylam grants Calando RNAi license
|
8/21/2006 | BT | Market Commentary: Dynavax says flu vaccine effective on divergent viral strains; Inverness to wrap $151.25 million PIPE
|
7/26/2006 | BT | Alnylam posts $9.9 million second quarter GAAP net loss
|
7/18/2006 | BT | Alnylam gets RNAi therapeutics patent
|
7/17/2006 | BT | Market Commentary: Threshold plunges over 51%; Genitope firms; Vivus dives; Progenics weak; Alnylam off
|
7/17/2006 | BT | Alnylam, Texas medical center to evaluate use of RNAi therapeutics in reducing cholesterol levels
|
7/17/2006 | BT | Alnylam, INEX expand RNAi systemic delivery research
|
7/11/2006 | BT | Market Commentary: Connetics stock regains 3%; Anadys adds 8% on new exec, moves Idenix, Vertex up, too; Xoma rises 5%
|
7/6/2006 | BT | Alnylam, Merck amend agreement to develop RNAi therapeutics
|
6/23/2006 | BT | Alnylam borrows $2.3 million to finance facility expansion, equipment
|
6/22/2006 | BT | Alnylam retains key elements in Kreutzer-Limmer I patent
|
6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
6/6/2006 | BT | Alnylam issued U.S. patent for making siRNAs
|
5/24/2006 | BT | Alnylam grants Bioneer license to Kreutzer-Limmer patents for RNai research
|
5/23/2006 | BT | Alnylam preclinical data shows efficacy for pandemic flu vaccine
|
5/23/2006 | BT | Market Commentary: Sirna slides 8% ahead of reduced deal; Auxilium gains; Alnylam off; bird flu names up after hours
|
5/9/2006 | BT | Alnylam obtains rights to RNAi delivery technology from CBR Institute
|
5/1/2006 | BT | Alnylam says RNAi respiratory treatment well-tolerated in two trials
|
5/1/2006 | BT | Market Commentary: Teva shares, convertibles gain on Zocor ruling; NeoPharm off amid downsizing; Alnylam, Idenix drop
|
4/12/2006 | BT | Alnylam, U.S. Army to work together on RNAi therapeutics for biodefense threats
|
4/5/2006 | BT | Market Commentary: Allergan rolls out $700 million note; Discovery falls on FDA request for more data; Human Genome up
|
3/27/2006 | BT | Alnylam signs deals with Inex, MIT for access to liposome delivery technology
|
3/27/2006 | BT | Alnylam: Researchers demonstrate in primates silencing of endogenous disease-causing gene
|
3/9/2006 | BT | Gen-Probe licenses HPA technology to Alnylam
|
2/28/2006 | BT | Alnylam grants RNAi license to Integrated DNA Technologies
|
2/23/2006 | BT | Market Commentary: Kos crashes on results, warning; GTC garroted by E.U. rejection; Nastech higher; Biovail mixed
|
2/21/2006 | BT | Alnylam's CEO: pact with Novartis includes 'significant' funding, profit-sharing structure
|
2/21/2006 | BT | Market Commentary: Alnylam up 10% on Novartis pact; OSI off; CuraGen clipped; Inspire comes in; Ista drops despite data
|
2/13/2006 | BT | Market Commentary: Amgen up after-hours as $4 billion convert emerges; Genentech off; Adolor down on deal; Alnylam up
|
2/1/2006 | BT | Market Commentary: Vertex gains; SGX debuts higher; Angiotech up; Alnylam off; DUSA dives; Endo slides; Isis bounces
|
1/31/2006 | BT | New Issue: Alnylam prices $66.5 million follow-on sale at $13 versus $13.44 close
|
1/24/2006 | BT | Alnylam second patent claims allowed broadly covering RNAi therapeutics
|
1/24/2006 | BT | Market Commentary: Nuvelo, Tercica toss hats in ring; Serono plunges on lack of suitors; Imclone results miss, seeks merger
|
1/23/2006 | BT | Alnylam to sell 5.1 million shares
|
1/17/2006 | BT | Alnylam announces U.S. patent broadly covering RNAi therapeutics
|
1/9/2006 | BT | Market Commentary: Human Genome, Amgen higher on license pact; Alnylam soars on 2006 view; NPS, Oscient up big
|
1/5/2006 | BT | Alnylam licenses RNAi products, services from Kreutzer-Limmer patents to Dharmacon
|
12/19/2005 | BT | Alnylam begins second phase 1 study of ALN-RSV01 for respiratory syncytial virus
|
12/14/2005 | BT | Alnylam receives Department of Defense funding to develop flu drug
|
12/7/2005 | BT | Alnylam begins phase 1 study of ALN-RSV01 for respiratory syncytial virus infection
|
11/23/2005 | BT | Alnylam Pharmaceuticals files $75 million shelf
|
11/1/2005 | BT | Alnylam submits FDA application to begin human trials of ALN-RSV01 anti-viral
|
9/13/2005 | PP | Market Commentary: Protein Design Labs pockets $100 million from collaboration; mergers may generate more biotech PIPEs
|
9/12/2005 | BT | Geron joins Myogen for Thursday; Cell Genesys up on back of Geron; OSI Pharma plummets on Tarceva
|
9/12/2005 | PP | Market Commentary: Three biotech deals lead PIPE issuance; Alnylam raises $58.5 million from stock offering
|
9/12/2005 | BTPP | New Issue: Alnylam Pharmaceuticals wraps $58.52 million private placement with Novartis
|
9/8/2005 | BT | Market Commentary: Myogen, NPS float follow-ons; Nektar halted during FDA panel; Sepracor up in face of generic filing
|